Veracyte Inc VCYT:NASDAQ

Last Price$19.90NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change-0.07(0.35%)
Bid (Size)$19.40 (1)
Ask (Size)$19.90 (95)
Day Low / High$19.30 - 20.45
Volume816.6 K
 

View Biotechnology IndustryPeer Comparison as of 06/30/2022

 

Veracyte Inc ( NASDAQ )

Price: $19.90
Change: -0.07 (0.35%)
Volume: 816.6 K
4:00PM ET 6/30/2022
 
 

Axsome Therapeutics Inc ( NASDAQ )

Price: $38.30
Change: +1.81 (4.96%)
Volume: 1.8 M
4:00PM ET 6/30/2022
 
 

Meridian Bioscience Inc ( NASDAQ )

Price: $30.42
Change: -1.08 (3.43%)
Volume: 804.8 K
4:00PM ET 6/30/2022
 
 

Myriad Genetics Inc ( NASDAQ )

Price: $18.17
Change: -0.27 (1.46%)
Volume: 494.1 K
4:00PM ET 6/30/2022
 
 

Immunitybio Inc ( NASDAQ )

Price: $3.72
Change: -0.05 (1.33%)
Volume: 1.1 M
4:00PM ET 6/30/2022
 

Read more news Recent News

Insider Buy: Veracyte
9:58AM ET 6/13/2022 MT Newswires

Marc Stapley, Director, Chief Executive Officer, on June 10, 2022, executed a purchase for 60,000 shares in Veracyte (VCYT) for $980,094. Following the...

Veracyte Says Study Data Show Utility of Prostate Genomic Classifier
12:27PM ET 6/03/2022 MT Newswires

Veracyte (VCYT) said Friday that newly published data reinforce the clinical utility of the Decipher Prostate genomic classifier to treat men experiencing...

--Morgan Stanley Adjusts Veracyte's Price Target to $23 from $25, Keeps Underweight Rating
1:04PM ET 5/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Raymond James Adjusts Veracyte's Price Target to $30 from $34, Keeps Outperform Rating
12:29PM ET 5/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Phone+1.650.243.6300
Number of Employees270
Recent SEC Filing06/16/20224
Chief Executive Officer & DirectorMarc A. Stapley
Chief Financial OfficerRebecca Chambers
Global Chief Scientific & Medical OfficerGiulia C. Kennedy
Executive Medical DirectorRichard T. Kloos

Company Highlights

Price Open$19.41
Previous Close$19.97
52 Week Range$14.85 - 54.13
Market Capitalization$1.4 B
Shares Outstanding71.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.57
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-19.22%
Return on Equity-4.52%

Analyst Ratings as of 05/05/2022

Buy
5
Overweight
1
Hold
1
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset